FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2041942173> ?p ?o ?g. }

• W2041942173 endingPage "354" @default.
• W2041942173 startingPage "347" @default.
• W2041942173 abstract "SUMMARY An increased prevalence of autoimmune thyroiditis (AT) in vitiligo patients is well known. The aim of this study was firstly, to evaluate the clinical course of patients with both vitiligo and AT and secondly, to identify additional autoimmune disorders affecting the thyroid gland in a large cohort of vitiligo patients. We analysed a study group of 106 vitiligo patients and 38 controls. A detailed thyroid examination including sonography was performed in all study participants. In addition, the study participants were HLA typed and screened for various autoimmune disorders. AT was significantly more frequent in vitiligo patients than in controls (21%versus 3%; P &lt; 0·01). In 12 of the 22 patients with AT, vitiligo was the initial disease preceding AT by 4–35 years. In the other 10 patients with AT, both vitiligo and AT were diagnosed within one year. There were two individuals with diabetes mellitus type 1 and a single patient with Addison's disease. Anti-nuclear antibody (ANA), anti-smooth muscle cell antibody, and parietal cell antibody levels occurred with a similar frequency in patients and controls. In all vitiligo patients with both elevated ANA levels and AT (n = 6), the atrophic but not the goitrous variant was diagnosed. These vitiligo patients with both AT and elevated ANA levels had a significantly smaller thyroid volume compared to the vitiligo patients with AT whose ANA levels were normal (6·7 ± 4·5 ml versus 13·4 ± 9·1 ml, respectively; P &lt; 0·05). The same was found in the entire study group: Thyroid volume of all vitiligo patients (with or without concomitant AT) was significantly smaller in the presence of ANA (6·9 ± 5·3 versus 10·5 ± 5·9 ml, espectively; P &lt; 0·05). However, this phenomenon was not observed in the control group. There was a trend for a decreased frequency of HLA-DR3 (6·7%versus 23%) in our study group, but after correction for the number of comparisons, no HLA-allele was statistically significant associated neither with vitiligo nor with multiple autoimmune diseases in our patient sample. Our findings suggest that AT is the most frequent autoimmune disease associated with vitiligo. In our patients, AT presented simultaneously or after the onset of vitiligo but not before. Elevated ANA levels were associated with the atrophic variant of AT and may affect the volume of the thyroid gland, and there was no statistically significant association with the HLA system." @default.
• W2041942173 created "2016-06-24" @default.
• W2041942173 creator A5030288902 @default.
• W2041942173 creator A5043274789 @default.
• W2041942173 creator A5061964438 @default.
• W2041942173 creator A5068530467 @default.
• W2041942173 creator A5069265383 @default.
• W2041942173 creator A5073632702 @default.
• W2041942173 date "2003-01-31" @default.
• W2041942173 modified "2023-10-11" @default.
• W2041942173 title "Autoimmune diseases in vitiligo: do anti-nuclear antibodies decrease thyroid volume?" @default.
• W2041942173 cites W122435564 @default.
• W2041942173 cites W1839335981 @default.
• W2041942173 cites W194556655 @default.
• W2041942173 cites W1969814939 @default.
• W2041942173 cites W1971939771 @default.
• W2041942173 cites W1975901029 @default.
• W2041942173 cites W1984833996 @default.
• W2041942173 cites W1989794781 @default.
• W2041942173 cites W1997821222 @default.
• W2041942173 cites W2010499716 @default.
• W2041942173 cites W2015083344 @default.
• W2041942173 cites W2018087979 @default.
• W2041942173 cites W2022071352 @default.
• W2041942173 cites W2032174342 @default.
• W2041942173 cites W2033817247 @default.
• W2041942173 cites W2046413596 @default.
• W2041942173 cites W2046536883 @default.
• W2041942173 cites W2054664456 @default.
• W2041942173 cites W2063733110 @default.
• W2041942173 cites W2066536713 @default.
• W2041942173 cites W2073919303 @default.
• W2041942173 cites W2074628873 @default.
• W2041942173 cites W2084797522 @default.
• W2041942173 cites W2089844380 @default.
• W2041942173 cites W2090044525 @default.
• W2041942173 cites W2106507718 @default.
• W2041942173 cites W2119829864 @default.
• W2041942173 cites W2123442942 @default.
• W2041942173 cites W2127594892 @default.
• W2041942173 cites W2137668891 @default.
• W2041942173 cites W2144111850 @default.
• W2041942173 cites W2145258710 @default.
• W2041942173 cites W2154086161 @default.
• W2041942173 cites W2413561122 @default.
• W2041942173 cites W2419664891 @default.
• W2041942173 cites W2482929793 @default.
• W2041942173 cites W2586865947 @default.
• W2041942173 doi "https://doi.org/10.1046/j.1365-2249.2003.02089.x" @default.
• W2041942173 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/1808638" @default.
• W2041942173 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12562399" @default.
• W2041942173 hasPublicationYear "2003" @default.
• W2041942173 type Work @default.
• W2041942173 sameAs 2041942173 @default.
• W2041942173 citedByCount "69" @default.
• W2041942173 countsByYear W20419421732012 @default.
• W2041942173 countsByYear W20419421732013 @default.
• W2041942173 countsByYear W20419421732014 @default.
• W2041942173 countsByYear W20419421732015 @default.
• W2041942173 countsByYear W20419421732016 @default.
• W2041942173 countsByYear W20419421732017 @default.
• W2041942173 countsByYear W20419421732018 @default.
• W2041942173 countsByYear W20419421732019 @default.
• W2041942173 countsByYear W20419421732020 @default.
• W2041942173 countsByYear W20419421732021 @default.
• W2041942173 countsByYear W20419421732022 @default.
• W2041942173 countsByYear W20419421732023 @default.
• W2041942173 crossrefType "journal-article" @default.
• W2041942173 hasAuthorship W2041942173A5030288902 @default.
• W2041942173 hasAuthorship W2041942173A5043274789 @default.
• W2041942173 hasAuthorship W2041942173A5061964438 @default.
• W2041942173 hasAuthorship W2041942173A5068530467 @default.
• W2041942173 hasAuthorship W2041942173A5069265383 @default.
• W2041942173 hasAuthorship W2041942173A5073632702 @default.
• W2041942173 hasBestOaLocation W20419421731 @default.
• W2041942173 hasConcept C126322002 @default.
• W2041942173 hasConcept C134018914 @default.
• W2041942173 hasConcept C159654299 @default.
• W2041942173 hasConcept C16005928 @default.
• W2041942173 hasConcept C163764329 @default.
• W2041942173 hasConcept C203014093 @default.
• W2041942173 hasConcept C2778696486 @default.
• W2041942173 hasConcept C2779075594 @default.
• W2041942173 hasConcept C2779980618 @default.
• W2041942173 hasConcept C2780176905 @default.
• W2041942173 hasConcept C50181227 @default.
• W2041942173 hasConcept C526584372 @default.
• W2041942173 hasConcept C555293320 @default.
• W2041942173 hasConcept C71924100 @default.
• W2041942173 hasConcept C90924648 @default.
• W2041942173 hasConceptScore W2041942173C126322002 @default.
• W2041942173 hasConceptScore W2041942173C134018914 @default.
• W2041942173 hasConceptScore W2041942173C159654299 @default.
• W2041942173 hasConceptScore W2041942173C16005928 @default.
• W2041942173 hasConceptScore W2041942173C163764329 @default.
• W2041942173 hasConceptScore W2041942173C203014093 @default.
• W2041942173 hasConceptScore W2041942173C2778696486 @default.
• W2041942173 hasConceptScore W2041942173C2779075594 @default.

• next